Prognostic Stratification and Outcomes in Brain Metastases from Nonanaplastic Follicular Cell-Derived Thyroid Carcinoma: Insights from a Multicenter Retrospective Study

Brain metastases (BMs) from nonanaplastic follicular cell-derived thyroid carcinoma (non-ATC) are rare with limited outcome data.
A large international multicenter cohort (n=189) reveals median overall survival (OS) of 15 months after BM diagnosis, with marked prognostic heterogeneity.
An evidence-based Graded Prognostic Assessment (non-ATC GPA) incorporating age, performance status, histology, extracranial metastases, and BM number effectively stratifies survival outcomes.
Exploratory validation using SEER data shows survival variation across GPA groups but indicates further validation is needed.